Abstract
Objective
To develop a simple clinical decision rule that could increase the yield of serum and urine protein electrophoresis (SPE/UPE) without loss of sensitivity.
Design
A cross-sectional study of inpatients with a SPE/UPE performed over a 5-year period (2001–2006) with complete data on electrolytes, globulins, full blood count, creatinine, age, and gender.
Setting
A tertiary-care general teaching hospital serving the Hunter Valley in New South Wales, with a referral population of over 1 million.
Participants
A total of 14,374 adult patients admitted between January 2001–November 2006.
Main outcome measures
Paraprotein on serum and/or urine protein electrophoresis (SPE/UPE).
Results
Five points were assigned for globulin >41 g/l, 3 points for age ≥60, 2 points for each of hemoglobin <121 and male gender, and 1 point for estimated glomerular filtration rate (eGFR) <60. Total scores of 0–5, 6–10, and ≥11 corresponded to positive likelihood ratios of an abnormal SPE/UPE of 1, 2.5, and 6.6, respectively. The predictive ability of this model was strong, with an area under the curve of ∼0.8. Results in the validation set were almost identical.
Conclusion
A clinical decision rule using simple clinical variables has the potential to improve the yield of SPE/UPE. This rule however needs to be verified prospectively.
Similar content being viewed by others
References
Beetham R, Howie N, Soutar R. Can opportunistic case-finding of paraproteins be clinically justified? Ann Clin Biochem. 2005;42:245–53.
Hughes M, Davidson DF, McColl M. Outcomes of discretionary laboratory testing of serum protein electrophoresis. Ann Clin Biochem. 2006;43:372–4.
Malacrida V, De Francesco D, Banfi G, Porta FA, Riches PG. Laboratory investigation of monoclonal gammopathy during 10 years of screening in a general hospital. J Clin Pathol. 1987;40:793–7.
McKenna P, Dewar M, Tiplady C, Jones K. Should the laboratory initiate requests for myeloma screening? Clin Chim Acta. 2005;355:S287.
Gabow PA. Disorders associated with an altered anion gap. Kidney Int. 1985;27:472–83.
Murray T, Long W, Narins RG. Multiple myeloma and the anion gap. N Engl J Med. 1975;292:574–5.
Flanagan NG, Ridway JC, Irving AG. The anion gap as a screening procedure for occult myeloma in the elderly. Journal of the Royal Society of Medicine. 1988;81:27–8.
De Troyer A, Stolarczyk A, De Beyl DZ, Stryckmans P. Value of anion-gap determination in multiple myeloma. N Engl J Med. 1977;29:858–60.
Cambareri J. Probability of myeloma in patients with low anion gap. Lancet. 1982;i:333–4.
Goldstein RJ, Lichtenstein NS, Souder D. The myth of the low anion gap. JAMA. 1980;243:1737–8.
Keshgegian AA. The low anion gap [letter]. JAMA. 1980;244:2047–8.
Mitnick PD. The low anion gap [letter]. JAMA. 1980;244:2047.
Narins RG, Emmett M. The low anion gap [letter]. JAMA. 1980;244:2047.
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266, Feb.
Nordin BEC, Need AG, Hartley TF, Philcox JC, Thomas DW. Improved method for calculating fractions in plasma: Reference values and effect of menopause. Clin Chem. 1989;35:14–7.
Data management. Stata Statistical Software: Release 10. College Station; TX: StataCorp LP; 2007.
Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statistics in medicine. 1996 Feb 28;154361–87.
Grimes DA, Schulz KF. Refining clinical diagnosis with likelihood ratios. Lancet. 2005;36594691500–5. Apr 23–29.
Tracey E, Chen S, Baker D, Bishop J, Jelfs P. Cancer in New South Wales. Incidence and mortality report 2004: Cancer Institute NSW; 2004.
Young B, Gleeson M. Audit of investigation and follow-up of patinets with raised monoclonal proteins. Aust Clin Rev. 1989;8:217–20.
Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–9.
Attia J. Moving beyond sensitivity and specificity: using likelihood ratios to help interpret diagnostic tests. Australian Prescriber. 2003;26:111–13.
Jaeschke R, Guyatt G, Lijmer J. Diagnostic Tests. In: Guyatt G, Rennie D, eds. Users’ Guides to the Medical Literature A Manual for Evidence-Based Clinical Practice: AMA Press; 2002. p. 121–40.
Jaeschke R, Guyatt G, Sackett DL. Users’ guides to the medical literature. III How to use an article about a diagnostic test. A. Are the results of the study valid? JAMA. 1994;271:389–91.
Jaeschke R, Guyatt G, Sackett DL. Users’ guides to the medical literature. III How to use an article about a diagnostic test. B. What are the results and will they help me care for my patient? JAMA. 1994;271:703–7.
Alyanakian M-A, Abbas A, Delarue R, Arnulf B, Aucouturier P. Free immunoglobulin light-chain serum levels in the follow-up of patients with monoclonal gammopathies: correlation with 24-hr urinary light-chain excretion. Am J Hematol. 2004;75:246–8.
Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet. 2003;361:489–91.
Acknowledgement
The authors declare that there was no conflict of interest, and there was no financial support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Thakkinstian, A., Tran, H., Reeves, G. et al. A Clinical Decision Rule to Aid Ordering of Serum and Urine Protein Electrophoresis for Case-Finding of Paraproteins in Hospitalized Inpatients. J GEN INTERN MED 23, 1688–1692 (2008). https://doi.org/10.1007/s11606-008-0712-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11606-008-0712-z